Enhertu
CHMP Recommends Approval of AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.
More Precise Response Markers Needed for Enhertu Amid HER2 Biomarker Disruption, Researchers Say
Premium
By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
NICE Not Backing AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Low Breast Cancer
Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.